Sign in
Enrolling by invitationPhase 4

Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males

Key facts

Who runs it
National Cheng-Kung University Hospital
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Enrolling by invitation
Phase
Phase 4
People taking part
661 people, planned
Started
9 Jul 2024
Expected to end
31 Jul 2032
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Drug: Bismuth Subcitrate 120 MG Oral Tablet
  • Esomeprazole 40mg
  • Metronidazole 250 MG
  • Tetracycline Pill
Record updated
7 November 2024

Who can take part

Age
18 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients who are > 18 years
  • H. pylori infection confirmed by histology of a gastric biopsy, a positive rapid urease test, or a positive 13C-urea breath test

Who cannot take part

  • Previous allergic reactions to any drugs in the bismuth quadruple therapy
  • History of H. pylori eradication
  • Severe comorbidities
  • Pregnant or breastfeeding women

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Helicobacter pylori eradication can reduce the risk of gastric cancer and decrease the recurrence of ulcers. However, in recent years, the increasing antibiotic resistance of Helicobacter pylori has reduced the efficacy of clarithromycin-based triple therapy to below 80%. The recent studies, including real-world data and a clinical trial, have consistently found that females have poorer eradication rate of Helicobacter pylori as compared with males. In previous clinical trial, investigators discovered that the efficacy of a 10-day bismuth quadruple therapy was not inferior to a 14-day bismuth quadruple therapy. However, it remains to be investigated whether the 10-day bismuth quadruple therapy is still non-inferior to the 14-day regimen in females.

Read full original descriptionShow less

This project continues the clinical trial to investigate whether the efficacy of the 10-day bismuth quadruple therapy in females is inferior to that in males and whether the 14-day bismuth quadruple therapy is superior to the 10-day regimen in females. The ultimate goal is to establish that male patients can use the 10-day bismuth quadruple therapy with fewer side effects and without compromising efficacy as compared with the 14-day regimen; while female patients are recommended to use the 14-day bismuth quadruple therapy as it would be more effective than the 10-day regimen.

Considering sex in research is becoming increasingly important, as females have more antibiotic-resistant Helicobacter pylori infection than males. The bismuth quadruple therapy can overcome most resistance issues. Researching and comparing the difference in the efficacy of bismuth quadruple therapy for Helicobacter pylori eradication between females and males are of significant clinical importance and align with current research trends.

The 3 groups in the trial

  • The 10-day bismuth-based quadruple therapy group for femalesExisting treatment, for comparison

    The female patients receive a 10-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Fuliclin 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.

    Treatment: Drug: Bismuth Subcitrate 120 MG Oral Tablet, Esomeprazole 40mg, Metronidazole 250 MG, and Tetracycline Pill

  • The 14-day bismuth-based quadruple therapy group for femalesExisting treatment, for comparison

    The female patients receive a 14-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Fuliclin 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.

    Treatment: Drug: Bismuth Subcitrate 120 MG Oral Tablet, Esomeprazole 40mg, Metronidazole 250 MG, and Tetracycline Pill

  • The 10-day bismuth-based quadruple therapy group for malesExisting treatment, for comparison

    The male patients receive a 10-day course of the bismuth-based quadruple therapy, including esomeprazole (Nexium 40 mg) 1 tab twice a day, bismuth subcitrate (dibismuth trioxide) (KCB F.C. 120 mg) 1 tab four times a day, metronidazole (Fuliclin 250 mg) 2 tab thrice a day, and tetracycline (250 mg) 2 tab four times a day.

    Treatment: Drug: Bismuth Subcitrate 120 MG Oral Tablet, Esomeprazole 40mg, Metronidazole 250 MG, and Tetracycline Pill

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Optimal Treatment Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Female Patients and Comparison of the Efficacy with That of Male Patients
Criteria questions
Built from NCT06509139, who can take part
Record updated
7 November 2024